

Yu-Tzu Tai

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/574031/yu-tzu-tai-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

201
papers

10,452
citations

50
h-index

101
g-index

213
ext. papers

12,151
ext. citations

5.3
avg, IF

5.75
L-index

#	Paper	IF	Citations
201	Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma. <i>Blood Cancer Journal</i> , 2022 , 12, 50	7	0
200	Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma. <i>Cancers</i> , 2021 , 13,	6.6	4
199	Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single cell level by QM-FISH. <i>Blood Advances</i> , 2021 ,	7.8	2
198	Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes. <i>Blood</i> , 2021 , 138, 723-723	2.2	
197	Identifying Long Noncoding RNA Dependencies Using CRISPR Interference (CRISPRi)-Based Platform in Multiple Myeloma. <i>Blood</i> , 2021 , 138, 894-894	2.2	
196	Gabarap Loss Mediates Immune Escape in High Risk Multiple Myeloma. <i>Blood</i> , 2021 , 138, 891-891	2.2	1
195	ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. <i>Blood Cancer Discovery</i> , 2021 , 2, 338-353	7	1
194	Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2021 , 2, 370-387	7	4
193	Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. <i>Blood Cancer Discovery</i> , 2021 , 2, 468-483	7	15
192	Integrated genomics and comprehensive validation reveal drivers of genomic evolution in esophageal adenocarcinoma. <i>Communications Biology</i> , 2021 , 4, 617	6.7	0
191	BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression. <i>Clinical Cancer Research</i> , 2021 ,	12.9	6
190	Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. <i>Leukemia</i> , 2021 ,	10.7	6
189	Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. <i>Leukemia</i> , 2021 , 35, 752-763	10.7	22
188	Progression signature underlies clonal evolution and dissemination of multiple myeloma. <i>Blood</i> , 2021 , 137, 2360-2372	2.2	9
187	Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. <i>Nature Communications</i> , 2021 , 12, 868	17.4	54
186	Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor. <i>Clinical Pharmacology: Advances and Applications</i> , 2021 , 13, 169-180	1.5	1
185	Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. <i>Blood Advances</i> , 2021 , 5, 2982-2986	7.8	2

184	VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo. <i>Blood Cancer Journal</i> , 2020 , 10, 110	7	12
183	IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients. <i>European Journal of Haematology</i> , 2020 , 105, 326-334	3.8	2
182	YWHAE/14-3-3 σ expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma. <i>Blood</i> , 2020 , 136, 468-479	2.2	3
181	BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma. <i>Cancers</i> , 2020 , 12,	6.6	24
180	The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. <i>Blood</i> , 2020 , 136, 2334-2345	2.2	26
179	Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, e652-e659	2	3
178	A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. <i>Leukemia</i> , 2020 , 34, 2150-2162	10.7	29
177	Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a. <i>Molecular Cancer Research</i> , 2020 , 18, 1063-1073	6.6	13
176	Pre-Clinical Validation of a Novel Erk1/2 and CDK4/6 Inhibitor Combination in Multiple Myeloma (MM). <i>Blood</i> , 2020 , 136, 22-23	2.2	
175	The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 1-3	2.2	0
174	A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma. <i>Blood</i> , 2020 , 136, 30-31	2.2	
173	TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment. <i>Blood</i> , 2020 , 136, 31-31	2.2	
172	Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 14-14	2.2	7
171	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2380-2389	2.2	46
170	Immunotherapeutic and Targeted Approaches in Multiple Myeloma. <i>ImmunoTargets and Therapy</i> , 2020 , 9, 201-215	9	9
169	The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. <i>Blood Advances</i> , 2020 , 4, 4195-4207	7.8	20
168	Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells. <i>Frontiers in Immunology</i> , 2020 , 11, 1771	8.4	29
167	Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling. <i>Leukemia</i> , 2020 , 34, 196-209	10.7	32

166	Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. <i>Leukemia</i> , 2020 , 34, 578-588	10.7	11
165	Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma. <i>Leukemia</i> , 2020 , 34, 567-577	10.7	13
164	APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. <i>Leukemia</i> , 2019 , 33, 426-438	10.7	40
163	A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. <i>Leukemia</i> , 2019 , 33, 171-180	10.7	39
162	B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 1143-1156	5.4	36
161	Preclinical Evaluation of CD8+ Anti-Bcma mRNA CAR T-Cells for the Control of Human Multiple Myeloma. <i>Blood</i> , 2019 , 134, 1811-1811	2.2	2
160	MEDI2228, a Novel Bcma Antibody-PBD Conjugate, Sensitizes Human Multiple Myeloma Cells to NK Cell-Mediated Cytotoxicity and Upregulates CD38 Expression in MM Cells. <i>Blood</i> , 2019 , 134, 3096-3096	2.2	3
159	AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo. <i>Blood</i> , 2019 , 134, 135-135	2.2	16
158	Loss-of-Function of Gabarap Impairs Bortezomib-Induced Anti-Tumor Immunity in Multiple Myeloma: Clinical Application. <i>Blood</i> , 2019 , 134, 134-134	2.2	2
157	The impact of response kinetics for multiple myeloma in the era of novel agents. <i>Blood Advances</i> , 2019 , 3, 2895-2904	7.8	14
156	Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. <i>Blood Advances</i> , 2019 , 3, 3248-3260	7.8	45
155	Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells. <i>Leukemia</i> , 2019 , 33, 766-771	10.7	44
154	Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. <i>Leukemia</i> , 2018 , 32, 1932-1947	10.7	59
153	Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 1454-1463	6.1	49
152	Widespread intronic polyadenylation diversifies immune cell transcriptomes. <i>Nature Communications</i> , 2018 , 9, 1716	17.4	66
151	Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. <i>Leukemia</i> , 2018 , 32, 2626-2635	10.7	31
150	Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. <i>Leukemia</i> , 2018 , 32, 1838-1841	10.7	24
149	SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads. <i>Clinical Cancer Research</i> , 2018 , 24, 6570-6582 ^{12.9}	12.9	33

148	Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. <i>Journal of Clinical Investigation</i> , 2018 , 128, 2487-2499	15.9	48
147	APRIL Is Significantly Elevated at All Stages of Multiple Myeloma (MM) and Interferes with Anti-Bcma Monoclonal Antibody-Mediated Cytolysis, Supporting the Clinical Evaluation of Bion-1301 As a Novel Therapeutic Approach in MM. <i>Blood</i> , 2018 , 132, 3209-3209	2.2	2
146	Anti-BCMA BiTE AMG 701 Potently Induces Specific T Cell Lysis of Human Multiple Myeloma (MM) Cells and Immunomodulation in the Bone Marrow Microenvironment. <i>Blood</i> , 2018 , 132, 592-592	2.2	15
145	Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. <i>Frontiers in Immunology</i> , 2018 , 9, 1821	8.4	131
144	Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1. <i>Frontiers in Immunology</i> , 2018 , 9, 1822	8.4	29
143	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. <i>Leukemia</i> , 2018 , 32, 2604-2616	10.7	90
142	Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017 , 23, 4290-4300	12.9	139
141	Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017 , 23, 5225-5237	12.9	19
140	Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era. <i>Experimental Hematology and Oncology</i> , 2017 , 6, 20	7.8	14
139	Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma. <i>Antibodies</i> , 2017 , 6,	7	9
138	MUC1-C is a target in lenalidomide resistant multiple myeloma. <i>British Journal of Haematology</i> , 2017 , 178, 914-926	4.5	15
137	Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma. <i>Oncotarget</i> , 2017 , 8, 18792-18801	3.3	50
136	MUC1-C drives MYC in multiple myeloma. <i>Blood</i> , 2016 , 127, 2587-97	2.2	60
135	APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. <i>Blood</i> , 2016 , 127, 3225-36	2.2	168
134	Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 13162-13167	11.5	89
133	Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. <i>Clinical Cancer Research</i> , 2016 , 22, 6099-6109	12.9	17
132	Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016 , 172, 735-44	4.5	88
131	The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. <i>Nature Communications</i> , 2016 , 7, 10258	17.4	61

130	Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Reverse Immunosuppression in Multiple Myeloma. <i>Blood</i> , 2016 , 128, 2106-2106	2.2	1
129	The Complex Landscape of Rearrangements in Smoldering and Symptomatic Multiple Myeloma Revealed By Whole-Genome Sequencing. <i>Blood</i> , 2016 , 128, 236-236	2.2	
128	Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 1225-34	6.3	72
127	Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. <i>Blood</i> , 2016 , 127, 1138-50	2.2	68
126	A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy. <i>Blood</i> , 2016 , 128, 249-52	2.2	41
125	A new era of immune therapy in multiple myeloma. <i>Blood</i> , 2016 , 128, 318-9	2.2	14
124	Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. <i>Blood</i> , 2016 , 128, 1590-603	2.2	99
123	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015 , 21, 4607-18	12.9	214
122	Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. <i>Cancer Discovery</i> , 2015 , 5, 972-87	24.4	67
121	Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment. <i>Experimental Hematology</i> , 2015 , 43, 168-176.e2	3.1	9
120	The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. <i>Clinical Cancer Research</i> , 2015 , 21, 2148-56	12.9	57
119	Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. <i>Cancer Research</i> , 2015 , 75, 4384-4397	10.1	69
118	Targeting B-cell maturation antigen in multiple myeloma. <i>Immunotherapy</i> , 2015 , 7, 1187-99	3.8	103
117	Combination of a Selective HSP90 α Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. <i>PLoS ONE</i> , 2015 , 10, e0143847	3.7	16
116	The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. <i>Nature Medicine</i> , 2015 , 21, 572-80	50.5	60
115	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. <i>Cell Reports</i> , 2015 , 12, 622-35	10.6	94
114	Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. <i>Annals of Hematology</i> , 2015 , 94, 257-64	3	39
113	Activation of Lysosomal Function and Reactive Oxygen Species Play Crucial Roles in SAR650984-Induced Direct Killing of Human Multiple Myeloma Cells with Mutated p53, Which Is Further Augmented By Pomalidomide. <i>Blood</i> , 2015 , 126, 4253-4253	2.2	

112	The KDM3A-KLF2-IRF4 Axis Maintains Myeloma Cell Survival. <i>Blood</i> , 2015 , 126, 3633-3633	2.2	
111	Dysregulated Nucleotide Excision Repair (NER) Is a New Target in Multiple Myeloma. <i>Blood</i> , 2015 , 126, 4187-4187	2.2	
110	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. <i>Nature Communications</i> , 2014 , 5, 2997	17.4	564
109	Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. <i>Blood</i> , 2014 , 123, 3128-38	2.2	273
108	Pyk2 promotes tumor progression in multiple myeloma. <i>Blood</i> , 2014 , 124, 2675-86	2.2	48
107	Differential and limited expression of mutant alleles in multiple myeloma. <i>Blood</i> , 2014 , 124, 3110-7	2.2	42
106	A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. <i>Blood</i> , 2014 , 123, 706-16	2.2	215
105	Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. <i>Cancer Research</i> , 2014 , 74, 4458-69	10.1	50
104	Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. <i>Blood</i> , 2014 , 124, 3250-9	2.2	98
103	Deep Sequencing of Immunoglobulin Loci Reveals Evolution of IgH Clone in Multiple Myeloma Patients over the Course of Treatment. <i>Blood</i> , 2014 , 124, 2005-2005	2.2	1
102	SAR650984 (SAR) Directly Promotes Homotypic Adhesion-Related Multiple Myeloma (MM) Cell Death and SAR-Induced Anti-MM Activities Are Enhanced By Pomalidomide, More Potently Than Lenalidomide. <i>Blood</i> , 2014 , 124, 2124-2124	2.2	2
101	Alternative Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A Large RNA-Seq Data Analysis of Newly-Diagnosed Myeloma Patients. <i>Blood</i> , 2014 , 124, 638-638	2.2	1
100	A Novel Anti-a Proliferation-Inducing Ligand Hapril.01A Monoclonal Antibody Targets Multiple Myeloma Cells in the Bone Marrow Microenvironment. <i>Blood</i> , 2014 , 124, 2098-2098	2.2	
99	Bone Marrow Microenvironment Regulates Alternative Splicing Events in Myeloma Cells through Downregulation of RNA Binding Protein Fox2. <i>Blood</i> , 2014 , 124, 4714-4714	2.2	
98	NFB Signaling and Mcl-1 Are Critical in B Cell Maturation Antigen-Promoted Multiple Myeloma Cell Growth and Survival. <i>Blood</i> , 2014 , 124, 3384-3384	2.2	
97	Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma. <i>Blood</i> , 2014 , 124, 27-27	2.2	1
96	Differential and Limited Expression of Mutant Alleles in Multiple Myeloma. <i>Blood</i> , 2014 , 124, 2007-2007	2.2	
95	A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. <i>Blood</i> , 2013 , 122, 1222-32	2.2	252

94	Bone Marrow Microenvironment Affects The Pathogenesis Of Multiple Myeloma Through Downregulation Of Alternative Splicing Factor Fox2 In Myeloma Cells. <i>Blood</i> , 2013 , 122, 3085-3085	2.2	1
93	Constitutive B-Cell Maturation Antigen (BCMA) Activation In Human Multiple Myeloma Cells Promotes Myeloma Cell Growth and Survival In The Bone Marrow Microenvironment Via Upregulated MCL-1 and NFB Signaling. <i>Blood</i> , 2013 , 122, 681-681	2.2	
92	Antibody-Based Therapies in Multiple Myeloma 2013 , 43-71		1
91	A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. <i>British Journal of Haematology</i> , 2012 , 157, 687-701	4.5	31
90	Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents. <i>British Journal of Haematology</i> , 2012 , 157, 718-31	4.5	24
89	Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. <i>Blood</i> , 2012 , 119, 2074-82	2.2	38
88	Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. <i>Blood</i> , 2012 , 120, 1877-87	2.2	150
87	Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. <i>Clinical Cancer Research</i> , 2012 , 18, 4850-60	12.9	57
86	Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM). <i>Blood</i> , 2012 , 120, 4039-4039	2.2	3
85	Targeting Aminopeptidases by Tosedostat (TST) (CHR2797), Alone and with LBH589, Induces Significant Cytotoxicity Against Human Multiple Myeloma (MM) Cells. <i>Blood</i> , 2012 , 120, 1847-1847	2.2	
84	Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. <i>British Journal of Haematology</i> , 2011 , 155, 349-61	4.5	25
83	Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. <i>Journal of Immunology</i> , 2011 , 186, 1840-8	5.3	649
82	Antibody-based therapies in multiple myeloma. <i>Bone Marrow Research</i> , 2011 , 2011, 924058		42
81	Significant biological role of sp1 transactivation in multiple myeloma. <i>Clinical Cancer Research</i> , 2011 , 17, 6500-9	12.9	44
80	Blockade of XBP1 Splicing by Inhibition of IRE1 β s a Promising Therapeutic Option in Multiple Myeloma. <i>Blood</i> , 2011 , 118, 133-133	2.2	2
79	Stroma-Derived Exosomes Mediate Oncogenesis in Multiple Myeloma. <i>Blood</i> , 2011 , 118, 625-625	2.2	2
78	Novel Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders,. <i>Blood</i> , 2011 , 118, 3990-3990	2.2	2
77	Immunomodulatory Effects of Histone Deacetylase 6 Inhibition in Suppressor Immune Cells in Multiple Myeloma. <i>Blood</i> , 2011 , 118, 128-128	2.2	

76	Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. <i>British Journal of Haematology</i> , 2010 , 149, 537-49	4.5	107
75	MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma. <i>Blood</i> , 2010 ,	2.2	11
74	Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. <i>Blood</i> , 2010 , 116, 3227-37	2.2	172
73	Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs. <i>Blood</i> , 2010 , 116, 3013-3013	2.2	1
72	Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma. <i>Blood</i> , 2010 , 116, 456-456	2.2	
71	Lenalidomide Enhances Multiple Myeloma Cytotoxicity Induced by a Novel Fc Domain-Engineered Anti-HM1.24 Monoclonal Antibody with Augmented NK Cell Degranulation. <i>Blood</i> , 2010 , 116, 4064-4064 ^{2.2}		
70	Emerging therapies for multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , 2009 , 14, 99-127	3.7	40
69	The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. <i>Clinical Cancer Research</i> , 2009 , 15, 4028-37	12.9	178
68	Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. <i>Cancer Cell</i> , 2009 , 16, 309-23	24.3	197
67	Monoclonal AntibodyBased Therapies in Human Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9, S22-S23		
66	CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. <i>Blood</i> , 2009 , 113, 4309-18	2.2	55
65	Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. <i>Blood</i> , 2009 , 114, 371-2.2	2.2	331
64	Potential Therapeutic Role of the Selective Adhesion Molecule (SAM) Inhibitor Natalizumab in Multiple Myeloma.. <i>Blood</i> , 2009 , 114, 1850-1850	2.2	1
63	Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo.. <i>Blood</i> , 2009 , 114, 3848-3848	2.2	2
62	Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication.. <i>Blood</i> , 2009 , 114, 608-608	2.2	3
61	XmAb□ 5592 Fc-Engineered Humanized Anti-HM1.24 Monoclonal Antibody Has Potent in Vitro and In Vivo Efficacy against Multiple Myeloma.. <i>Blood</i> , 2009 , 114, 609-609	2.2	2
60	Phenotypic and Functional Effects of Novel HDAC Inhibitor LBH589 On Human Lymphocyte Populations.. <i>Blood</i> , 2009 , 114, 3681-3681	2.2	
59	Immunomodulatory EFFECTS of Lenalidomide and Pomalidomide ON INTERACTION of TUMOR and BONE MARROW Accessory CELLS IN MULTIPLE MYELOMA.. <i>Blood</i> , 2009 , 114, 950-950	2.2	

58	Whole Genome Paired End Sequencing Identifies Genomic Evolution in Myeloma.. <i>Blood</i> , 2009 , 114, 2846-2846		1
57	A NOVEL Aurora A Kinase INHIBITOR MLN8237 Induces Cytotoxicity and CELL Cycle Arrest IN MULTIPLE MYELOMA.. <i>Blood</i> , 2009 , 114, 3830-3830	2.2	
56	HDAC Inhibition by LBH589 Affects Phenotype and Function of Human Dendritic Cells.. <i>Blood</i> , 2009 , 114, 1646-1646	2.2	
55	Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. <i>Blood</i> , 2008 , 112, 1329-37	2.2	366
54	The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo. <i>Nature Precedings</i> , 2008 ,		2
53	Antibody and Other Immune-Based Therapies for Myeloma 2008 , 167-202		
52	Phenotypic and Functional Effects of Novel Akt Inhibitor Perifosine on Immune System.. <i>Blood</i> , 2008 , 112, 1555-1555	2.2	
51	Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs. <i>Blood</i> , 2008 , 112, 2648-2648	2.2	
50	TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application. <i>Blood</i> , 2008 , 112, 2737-2737	2.2	
49	Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. <i>British Journal of Haematology</i> , 2007 , 138, 783-91	4.5	94
48	Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 7516-21	11.5	173
47	Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. <i>Blood</i> , 2007 , 110, 1656-63		103
46	TH17 Pathway and Associated Pro-Inflammatory Cytokines Promote Immune Dysfunction in Myeloma.. <i>Blood</i> , 2007 , 110, 3517-3517	2.2	1
45	Identification of CS1 Peptides for Induction of Antigen-Specific CTLs in Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 1611-1611	2.2	1
44	Low Levels of Circulating CS1, a Newly Identified Multiple Myeloma (MM) Antigen for a Novel Humanized HuLuc63 Monoclonal Antibody, Is Detected in MM Patient Sera and Correlates with Active Disease.. <i>Blood</i> , 2007 , 110, 1509-1509	2.2	1
43	Emerging Therapies for Multiple Myeloma. <i>American Journal of Cancer</i> , 2006 , 5, 141-153		2
42	Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. <i>Cancer Research</i> , 2006 , 66, 6675-82	10.1	187
41	Inhibition of ERK1/2 Activity by the MEK1/2 Inhibitor AZD6244 (ARRY-142886) Induces Human Multiple Myeloma Cell Apoptosis in the Bone Marrow Microenvironment: A New Therapeutic Strategy for MM.. <i>Blood</i> , 2006 , 108, 3460-3460	2.2	1

40	The MEK1/2 Inhibitor AZD6244 (ARRY-142886) Downregulates Constitutive and Adhesion-Induced c-MAF Oncogene Expression and Its Downstream Targets in Human Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 3463-3463	2.2	2
39	Anti-Myeloma Activity of the Small-Molecule Aurora Kinase Inhibitor VE465.. <i>Blood</i> , 2006 , 108, 3468-3468.2	2.2	2
38	Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications.. <i>Blood</i> , 2006 , 108, 3485-3485	2.2	2
37	Novel Murine Model To Study Modulation of Genes and Molecular Pathways Induced Following In Vivo Interaction between Multiple Myeloma Cells and Human BM Milieu.. <i>Blood</i> , 2006 , 108, 3409-3409	2.2	
36	The Small-Molecule VEGF-Receptor Inhibitor Pazopanib (GW786034B) Targets Both Tumor and Endothelial Cells in Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 5003-5003	2.2	
35	Clinical, Radiographic, and Biomarker Characterization of Multiple Myeloma Patients with Bisphosphonate Associated Osteonecrosis of the Jaw.. <i>Blood</i> , 2006 , 108, 3591-3591	2.2	
34	The BAFF Inhibitor AMG523 Blocks Adhesion and Survival of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment: Clinical Implication.. <i>Blood</i> , 2006 , 108, 3452-3452	2.2	1
33	In Vitro Generation of Highly Purified Functional Invariant NKT Cells in Multiple Myeloma: A Strategy for Immunotherapy.. <i>Blood</i> , 2006 , 108, 5104-5104	2.2	
32	Upregulation of c-Jun Induces Cell Death Via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 3415-3415	2.2	
31	Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. <i>Cancer Research</i> , 2005 , 65, 5898-906	10.1	131
30	Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. <i>Cancer Research</i> , 2005 , 65, 11712-20	10.1	149
29	Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052.. <i>Blood</i> , 2005 , 106, 3378-3378	2.2	1
28	The Role of B Cell-Activating Factor (BAFF) in the Biology of Multiple Myeloma (MM).. <i>Blood</i> , 2005 , 106, 3380-3380	2.2	1
27	CD27-Mediated Apoptosis Is Dependent on Siva-Induced Caspase Activation in Human Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 3398-3398	2.2	0
26	Bone Marrow Mast Cells Are Significantly Increased in Patients with Waldenstrom's Macroglobulinemia, and Their Number Following Therapeutic Intervention Is Dependent on Extent of Response.. <i>Blood</i> , 2005 , 106, 980-980	2.2	2
25	Alkylphosphocholine Perifosine Inhibits Myeloma Cell Growth While Inducing Myeloid Hyperplasia in a Murine Myeloma Model.. <i>Blood</i> , 2005 , 106, 1579-1579	2.2	
24	Chromosomal Deletions and Amplifications in Multiple Myeloma Detected by 500K Single Nucleotide Polymorphism Array Analysis.. <i>Blood</i> , 2005 , 106, 1551-1551	2.2	
23	Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications.. <i>Blood</i> , 2005 , 106, 5150-5150	2.2	

22	Novel Hydroxamic Acid-Derived HDAC Inhibitor LBH589 Potently Activates Intrinsic and Extrinsic Apoptotic Pathways, and Induces Tubulin Hyperacetylation in Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 1578-1578 ^{2,2} 1		
21	Role of BAFF in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment.. <i>Blood</i> , 2005 , 106, 627-627	2.2	
20	In Vitro Generation of Highly-Purified Functional Invariant NKT Cells: A Strategy for Immunotherapy in Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 5183-5183	2.2	
19	Up-Regulation of c-Jun contributes to the Induction of Apoptosis by Adaphostin in Human Multiple Myeloma Cells.. <i>Blood</i> , 2005 , 106, 1585-1585	2.2	
18	Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. <i>Cancer Research</i> , 2004 , 64, 2846-52	10.1	110
17	Mitochondria and Caspase-Independent Cell-Death Triggered by GCS-100, a Novel Carbohydrate-Based Therapeutic in Multiple Myeloma (MM) Cells.. <i>Blood</i> , 2004 , 104, 2456-2456	2.2	1
16	Enhanced Cytotoxicity of Monoclonal Antibody SGN-40 and Immunomodulatory Drug IMiD3 Against Human Multiple Myeloma.. <i>Blood</i> , 2004 , 104, 1498-1498	2.2	
15	JNK Activation and Fas Up-Regulation Precede Proteasomal Degradation of Topoisomerase I in SN38-Mediated Cytotoxicity Against Multiple Myeloma.. <i>Blood</i> , 2004 , 104, 3413-3413	2.2	3
14	SDX-101 Is Cytotoxic and Overcomes Drug Resistance in Multiple Myeloma.. <i>Blood</i> , 2004 , 104, 3466-3466.2		
13	Increased TCF-4 Expression Correlates with Reduced Caspase-3 Induction and Confers Resistance to Bortezomib.. <i>Blood</i> , 2004 , 104, 285-285	2.2	1
12	Inhibition of Human Plasmacytoma Cell Growth by a Novel JAK Kinase Inhibitor.. <i>Blood</i> , 2004 , 104, 644-644		
11	CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. <i>Blood</i> , 2003 , 101, 2762-9	2.2	98
10	Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. <i>Cancer Research</i> , 2003 , 63, 5850-8	10.1	138
9	Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implications. <i>Experimental Hematology</i> , 2002 , 30, 212-20	3.1	39
8	CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. <i>Blood</i> , 2002 , 99, 1419-27	2.2	72
7	Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. <i>Blood</i> , 2001 , 98, 210-6	2.2	773
6	Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. <i>Blood</i> , 2001 , 98, 428-35	2.2	358
5	Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. <i>Blood</i> , 2000 , 96, 2943-2950	2.2	772

4	Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage. <i>Journal of Immunology</i> , 2000 , 165, 6347-55	5.3	44
3	BAD partly reverses paclitaxel resistance in human ovarian cancer cells. <i>Oncogene</i> , 1998 , 17, 2419-27	9.2	27
2	Adenovirus Vector-Based Purging of Multiple Myeloma Cells. <i>Blood</i> , 1998 , 92, 4591-4601	2.2	58
1	Principles of pathway directed therapy	110-120	